Christopher Granger, MD: Patient Tolerability of Anticoagulants

Video

Christopher Granger, MD, Duke University Medical Center also spoke at the European Society of Cardiology COngress 2016 about the issues surrounding patients' tolerability of anticoagulants and other drugs.

Christopher Granger, MD, Duke University Medical Center also spoke at the European Society of Cardiology Congress 2016 about the issues surrounding patients' tolerability of anticoagulants and other drugs. "About half of peopel who start on a drug proven to be effective stop it within a year, because of intolerance to the drug, ineffectiveness, or sometimes because of lack of adherence - cause as human beings we may not be so good at reliablytaking things," Granger explained. So, at ESC 2016, Granger and team were reporting that apixaban was better tolerated than warfarin.

Related Videos
HCPLive Five at ACC 2024 | Image Credit: HCPLive
Ankeet Bhatt, MD, MBA | Credit: X.com
Ankeet Bhatt, MD, MBA | Credit: X.com
Sara Saberi, MD | Credit: University of Michigan
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Albert Foa, MD, PhD | Credit: HCPLive
Veraprapas Kittipibul, MD | Credit: X.com
Heart Failure stock imagery. | Credit: Fotolia
© 2024 MJH Life Sciences

All rights reserved.